期刊文献+

双磷酸盐和^(153)Sm-EDTMP联合治疗肺癌骨转移80例量效关系探讨 被引量:1

Dose-effectiveness of samarium-153-EDTMP combined with pamidronate disodium for the treatment of lung cancer with bone metastases
下载PDF
导出
摘要 目的探讨核素153Sm-EDTMP与双磷酸盐(博宁)联用治疗肺癌骨转移的量效关系。方法将80例肺癌骨转移患者随机分为A、B、C、D组各20例,A组静注153Sm-EDTMP 1.0 mCi/kg(全量);B组将博宁90 mg(全量)加入500 ml生理盐水中缓慢静滴,不少于4 h;C组应用全量153Sm-EDTMP间隔3~5 d后应用全量博宁;D组用药同C组,但剂量减半。均为每月1次,1 d/次。连续使用3次后观察各组临床疗效及不良反应,对各组量效关系进行分析。结果A、B、C、D组骨痛有效率分别为70%、75%、90%、85%;KPS评分提高率分别为70%、80%、90%、85%;影像学改善率分别为20%、25%、40%、30%。血液学不良反应发生率以应用153Sm-EDTMP组较高,主要是Ⅰ~Ⅱ级白细胞和血小板下降;药物经济学分析示D组疗效接近C组,高于A、B组;治疗费用接近B组,低于A、C组。结论半量博宁联合153Sm-EDTMP治疗肺癌骨转移效果可靠,不良反应小,且花费低。 Objective To investigate the dose-effectlveness of samarium-153-EDTMP combined with pamidronate disodium for the treatment of lung cancer with bone metastases. Methods 80 lung cancer patients with bone metastasis were divided into 4 groups randomly. Groap A was given 90 mg pamidrenate ,group B was given 1.0 mCi/kg of Sm-153 ,group C was given 90 mg pamidronate combined with 1.0 mCi/kg of Sm-153 sequentially, group D was given 45 mg pamidronate and 0.5 mCi/kg of Sm-153 ,all by intravenous injection and once a month. Clinical effects and adverse events were observed ,and dose-effectiveness was analyzed. Resttlts The effective rate of pain in four groups were 75% ,70% ,90% ,85% ,the improvement rate of KPS score were 80% ,70% ,90% ,85%, the improvement rate of imageology were 25% ,20% ,40%, 30% . Suppression of platehts and white blood cell counts( grade Ⅰ-Ⅱ ) were the most common adverse events in group B and C. The total 3 months cost of group D was the most benefical for the patient. Conclusion Half dose of samarium- 153-EDTMP combined with pamidronate disodium is effective and less cost for the treatment of lung cancer with bone metastases.
出处 《山东医药》 CAS 北大核心 2009年第19期10-12,共3页 Shandong Medical Journal
基金 上海市卫生局青年基金资助项目(054Y48)
关键词 博宁 153SM-EDTMP 肺肿瘤 肺癌 骨转移 剂量效应关系 pamidronatedisodium samarium-153-EDTMP lung cancer bone metastases dose-effectivenessand
  • 相关文献

参考文献7

二级参考文献49

  • 1唐谨,李家琇,曹秀华,刘琳,郑容,陈盛祖,吴文凯,刘跃民,王凡,金小海.^(153)Sm-EDTMP治疗多发性骨转移癌的临床研究[J].中华核医学杂志,1994,14(4):211-214. 被引量:53
  • 2刘枫,周同冲,任志刚,刘淑华,刘致俊.^(89)Sr联合局部外照射治疗鼻咽癌多发性骨转移瘤疗效评价[J].中华放射医学与防护杂志,2005,25(3):259-260. 被引量:2
  • 3谭天秩,邓候富,梁正路.^(153)Sm-EDTMP治疗骨转移瘤的临床观察[J].中华核医学杂志,1995,15(1):23-25. 被引量:60
  • 4Theriault RL, Lipton A, Hortobagyi GN, et al. Pamidronate reduces skeletal morbidity in with advanced breast cancer and lytic bone lesion: a randomized placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group [J].J Clin Oneol, 1999,17(3):846-854.
  • 5Foumier P, Boissier S, Filleur S ,et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rates [J]. Cancer Res, 2002,62(22) :6538-6544.
  • 6张天泽 徐光炜.肿瘤学[M].天津:天津科学技术出版社,1996.1209.
  • 7孙达.放射性核素骨显像[M].杭州:浙江大学出版社,2000.32-33.
  • 8Serafini AN. Samarium Sm-153 lexidronam for the palliation of bone pain associated with metastases. Cancer, 2000, 88 ( Suppl 12 ) : 2934-2939.
  • 9Juweid ME, Zhang CH, Blumenthal RD, et al. Factors influencing hematologic toxicity of radioimmunotherapy with ^131I-labeled-anticarcinoembryonic antigen antibodies. Cancer, 1997, 80 ( Suppl 12 ) :2749-2753.
  • 10Kasalicky J, Krajska V. The effect of repeated strontium-89 chloride therapy on bone pain palliation in patients with skeletal cancer metastases. Eur J Nucl Med, 1998,25:1362-1367.

共引文献9

同被引文献11

  • 1张青,胡云,张莉,苏红媛,叶恒光.核素骨显像在肺癌骨转移诊断中的应用[J].重庆医学,2005,34(8):1136-1136. 被引量:9
  • 2黄河清,章五一,庞倩.综合疗法治疗非小细胞肺癌骨转移120例临床分析[J].广东医学院学报,2005,23(5):582-583. 被引量:3
  • 3赵新华,张宜生,张华,李庆,阳秀芝,蒋显勇,张忠山,谢菊英.博宁治疗骨转移癌36例疗效观察[J].中国肿瘤临床与康复,2006,13(1):91-92. 被引量:4
  • 4吴涛,崔东海,王晓芳.非小细胞肺癌骨转移疗效对比研究[J].医药论坛杂志,2006,27(17):45-46. 被引量:4
  • 5Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity[J]. Clin Cancer Res, 2006, 12(20) :6243.
  • 6Sugiura H,Yamada K,Sugiura T,et al. Predictors of survival in patients with bone metastasis of lung cancer[J]. Clin Orthop Relat Res,2008,466(3) : 729.
  • 7Gebba V, Galetta D, Riceardi F, et al. Vinorelbine plus cisplatin versus cisplatin plus vindesine and mitomg MC in stage ⅢB-Ⅳ non-small cell lung carcin oma:a prospective randomized study[J]. Lung cancer,2002,37(2): 179.
  • 8Bobilev D, Lavrenkov K, Cohen Y, et al. Vinorelbine plus cisplatin as first-line combi-nation chemotherapy for ad vaneed non-small cell lung cancer Retrosp-ective analysis [J]. Oncology forum, 2004,7 ( 1 ) : 3.
  • 9Mori K,Kamiyama R,Kondo T,et al. Phase Ⅱ study of the combination of vinorelbine and cisplatin in advanced non-small cell lung cancer[J]. Cancer chemotherapy pharmacol,2004,53(2) :129.
  • 10Manus MP, Hicks RJ, Matthews JP,et al. Metabolic(fdgpet) response after radical- radiotherapy for non-small cell lung cancer correlates with patterns of failor[J]. Int J Lung Cancer,2005,49(1) :95.

引证文献1

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部